Diagonaltx
Watertown, US · 4 known investors
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases. Its DIAGONAL Product Engine uses computational and experimental methods to identify clustering antibodies across receptor classes, with a lead candidate (DIAG723) in a Phase 1/2 trial for Hereditary Hemorrhagic Telangiectasia.
AI & Machine LearningBiotechHealthtech
Investors · 4
Frequently asked questions
- What does Diagonaltx do?
- Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases. Its DIAGONAL Product Engine uses computational and experimental methods to identify clustering antibodies across receptor classes, with a lead candidate (DIAG723) in a Phase 1/2 trial for Hereditary Hemorrhagic Telangiectasia.
- Who are Diagonaltx's investors?
- Diagonaltx's investors include Atlas Venture, EcoR1 Capital, Frazier Life Sciences, Sanofi Ventures.
- Where is Diagonaltx headquartered?
- Diagonaltx is headquartered in Watertown, US.